BACKGROUND: Surgical therapy for early oropharyngeal carcinoma leads to excellent oncologic results but often requires adjuvant radiotherapy. The purpose of this study was to identify prognostic factors that worsen the outcome of limited oropharyngeal carcinoma treated with surgery ± adjuvant therapy. METHODS: Two hundred sixty-six patients were retrospectively evaluated between 1980 and 2007. RESULTS: Overall 5-year disease-specific survival (DSS) was 88.7% and local control (LC) was 93.3%. The univariate analysis showed a significant difference in DSS between pT1 and pT2 oropharyngeal carcinoma (DSS, 94.0% vs 81.2%; p = .008) and patients with tumor depth greater than 5 mm (DSS, 94.5% vs 78.9%; p = .031). No difference could be found as to N classification, marginal status, p16 human papillomavirus (HPV) status, type of treatment, and adjuvant radiotherapy. CONCLUSION: Primary surgical treatment is an effective therapy of limited oropharyngeal carcinoma. Patients with pT2 status and tumor depth of more than 5 mm show a significantly worse survival rate and should be further investigated in future clinical trials.
BACKGROUND: Surgical therapy for early oropharyngeal carcinoma leads to excellent oncologic results but often requires adjuvant radiotherapy. The purpose of this study was to identify prognostic factors that worsen the outcome of limited oropharyngeal carcinoma treated with surgery ± adjuvant therapy. METHODS: Two hundred sixty-six patients were retrospectively evaluated between 1980 and 2007. RESULTS: Overall 5-year disease-specific survival (DSS) was 88.7% and local control (LC) was 93.3%. The univariate analysis showed a significant difference in DSS between pT1 and pT2 oropharyngeal carcinoma (DSS, 94.0% vs 81.2%; p = .008) and patients with tumor depth greater than 5 mm (DSS, 94.5% vs 78.9%; p = .031). No difference could be found as to N classification, marginal status, p16 human papillomavirus (HPV) status, type of treatment, and adjuvant radiotherapy. CONCLUSION: Primary surgical treatment is an effective therapy of limited oropharyngeal carcinoma. Patients with pT2 status and tumor depth of more than 5 mm show a significantly worse survival rate and should be further investigated in future clinical trials.
Authors: Don-Felix Ryzek; Konstantinos Mantsopoulos; Julian Künzel; Philipp Grundtner; Johannes Zenk; Heinrich Iro; Georgios Psychogios Journal: Biomed Res Int Date: 2014-02-25 Impact factor: 3.411
Authors: Georgios Psychogios; Christoph Alexiou; Abba Agaimy; Kathrin Brunner; Michael Koch; Konstantinos Mantsopoulos; Andrea Tomppert; Heinrich Iro Journal: Cancer Med Date: 2014-03-10 Impact factor: 4.452
Authors: Georgios Psychogios; Konstantinos Mantsopoulos; Abbas Agaimy; Kathrin Brunner; Elisabeth Mangold; Johannes Zenk; Heinrich Iro Journal: Biomed Res Int Date: 2014-03-31 Impact factor: 3.411